Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
No published Phase 2 or Phase 3 trial of subcutaneous BPC-157 in healthy adults exists at the time of writing
Research from 2024 demonstrated significant improvement in inflammatory bowel conditions, with patients showing reduced C-reactive protein levels and improved tissue healing markers
Community subcutaneous plans should not be presented as trial-tested or approved dosing
Dose: 0.25mg daily for weeks 1-2, increased to 0.5mg daily for weeks 3-6 Administration: Subcutaneous injection, rotating between deltoid area and upper chest near the shoulder Duration: 6 weeks total Supporting therapy: Light stretching daily, avoided overhead movements until week 4 Three months out from finishing the protocol, my shoulder still feels solid
For those who do require supplementation, understanding appropriate dosage is important
The extended shelf life comes from the pen formulation, per the Novo Nordisk prescribing information (2022)
.jpg)